露凡 梅

MMP-9–responsive stealth-to-activation liposomes enable tumor-selective PD-L1 degradation via dual-PEG shedding

Abstract PD-1/PD-L1 blockade benefits patients across > 20 cancer types, yet durable responses remain limited and antibody therapies only transiently engage the axis while causing systemic immune-related adverse events. We report lipoRDPA, a rationally designed liposomal degrader...